Acorda Therapeutic (ACOR) volatility at 55 into extension of PDUFA
Down)
Acorda Therapeutic (Nasdaq: ACOR) is recently down 25c to $23.43. ACOR announced an extension of the FDA action date for fampridine, a treatment to help walking function in MS, to January 22. ACOR January option implied volatility of 50 is below its six-month average of 90, according to Track Data, suggesting decreasing price movement. Paul Foster
You May Also Be Interested In
- Renren (RENN) Volatility Rises Amid Facebook Weakness; Shares Break Below Key Levels
- 2012 Economic Outlook - Report Highlights Acorda Therapeutics Inc and Pharmacyclics, Inc.
- CVR Energy (CVI) Volatility Nearly Double; Icahn Now Holds 80% of Co. Shares
Create E-mail Alert Related Categories
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
